CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioVersys AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioVersys AG
c/o Technologiepark, Hochbergstrasse 60c
Phone: +41 615515120p:+41 615515120 BASEL, 4057  Switzerland Ticker: BIOVBIOV
Business Summary
BioVersys AG is a Switzerland based company engaged in the development of biopharmaceuticals. The Company focuses on developing antibacterial therapies to address antimicrobial resistance (AMR), particularly targeting pathogens identified as critical by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Their key product is BV100, which is a clinical-stage antibacterial compound. It is a small-molecule therapeutic designed to treat serious hospital infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) lung and bloodstream infections. The primary goal of this product is to reduce mortality in intensive care patients where current treatments are ineffective. The Company's portfolio includes also other medicines in various stages of development: BV200, Alpibectir, BV500, BV Discovery.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Seng ChinMah 66 1/1/2011
Chief Executive Officer, Co-Founder, Board Member MarcGitzinger 44 12/1/2020 1/1/2010
Chief Financial Officer HernanLevett 50 1/1/2023 1/1/2023
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 5,845,886 (As of 10/2/2025)
Stock Exchange: SWF


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, October 27, 2025